Fighting AMR by the antifungal drug candidate alligamycin
Invasive fungal pathogens cause 3.8 millions of death worldwide. There are only four main classes of antifungal drugs and they are limited by toxicity, drug-drug interactions and antibiotic resistance. This led to a high mortality in immunocompromised patients.